Back

Cryptochrome Loss Drives COPD-like Lung Pathology through Disrupted Alveolar Epithelial Proliferation and Immune Homeostasis

Mills, T. W.; Han, C.; Lim, J. Y.; Koike, N.; Kim, S. Y.; Wi, J.; Liu, H.; Wang, Y.; Yagita, K.; Alcorn, J. L.; Chen, Z.; Yoo, S.-H.

2026-05-21 genetics
10.64898/2026.05.19.726266 bioRxiv
Show abstract

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by alveolar destruction, impaired epithelial regeneration and chronic inflammation. While circadian disruption has been linked to COPD pathogenesis, the cellular mechanisms remain unclear. Here, we identify the core clock components Cryptochrome 1 and 2 (Cry1/2) as essential regulators of alveolar epithelial cell proliferation and pulmonary immune homeostasis. Cry1/2 double knockout (dKO) mice exhibit spontaneous emphysema-like pathology, including airspace enlargement, increased lung compliance, and inflammatory cell infiltration without environmental insults. Mechanistically, Cry1/2-deficient alveolar epithelial cells display reduced proliferative capacity, and transcriptomic profiling revealed a pronounced shift toward a more proximal airway-like phenotype. Notably, these cells share a gene signature with human COPD lungs in pathways involving immune regulation. Furthermore, Cry1/2-deficient macrophages show elevated responsiveness to LPS. Bone marrow (BM) transplantation revealed that mice receiving Cry1/2 dKO BM suffer from enhanced lung inflammation without airspace enlargement, supporting a critical role of epithelial Cry1/2 in maintaining alveolar integrity. Importantly, treatment with Nobiletin, a circadian rhythm-modulating compound, mitigates NF-{kappa}B activation and ameliorates lung inflammation and structural damage in Cry1/2 dKO mice. These findings establish CRY1/2 as critical circadian regulators of epithelial cell proliferation and immune homeostasis, and highlight the therapeutic potential of targeting circadian pathways in COPD.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 3%
22.4%
2
JCI Insight
241 papers in training set
Top 0.4%
6.8%
3
Cell Reports
1338 papers in training set
Top 10%
4.8%
4
Nature Metabolism
56 papers in training set
Top 0.4%
4.8%
5
Nature Aging
51 papers in training set
Top 0.4%
4.3%
6
Science Translational Medicine
111 papers in training set
Top 0.7%
4.0%
7
Nature Genetics
240 papers in training set
Top 2%
4.0%
50% of probability mass above
8
Developmental Cell
168 papers in training set
Top 5%
3.6%
9
Science Advances
1098 papers in training set
Top 13%
2.1%
10
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 30%
1.9%
11
eLife
5422 papers in training set
Top 38%
1.9%
12
Human Molecular Genetics
130 papers in training set
Top 2%
1.7%
13
Nature Immunology
71 papers in training set
Top 1%
1.5%
14
PLOS Genetics
756 papers in training set
Top 10%
1.5%
15
EMBO reports
136 papers in training set
Top 3%
1.5%
16
EMBO Molecular Medicine
85 papers in training set
Top 2%
1.3%
17
The EMBO Journal
267 papers in training set
Top 3%
1.2%
18
The Journal of Infectious Diseases
182 papers in training set
Top 3%
1.2%
19
Nature Cell Biology
99 papers in training set
Top 4%
1.1%
20
Cell Research
49 papers in training set
Top 2%
1.1%
21
Advanced Science
249 papers in training set
Top 15%
1.1%
22
Journal of Clinical Investigation
164 papers in training set
Top 5%
0.9%
23
Scientific Reports
3102 papers in training set
Top 70%
0.9%
24
mBio
750 papers in training set
Top 10%
0.9%
25
American Journal of Respiratory and Critical Care Medicine
39 papers in training set
Top 0.8%
0.9%
26
Molecular Therapy
71 papers in training set
Top 2%
0.9%
27
Nature
575 papers in training set
Top 15%
0.8%
28
American Journal of Respiratory Cell and Molecular Biology
38 papers in training set
Top 0.7%
0.8%
29
PLOS Biology
408 papers in training set
Top 20%
0.7%
30
Experimental & Molecular Medicine
14 papers in training set
Top 0.2%
0.7%